Skip to main content
Bora Pharmaceuticals Co., Ltd. logo

Bora Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 6472 ISIN · TW0006472004 LEI · 254900MK7O5C2UX1SY03 TW Manufacturing
Open in API
Filings indexed 48 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country TW Taiwan
Listing TW 6472

About Bora Pharmaceuticals Co., Ltd.

https://bora-corp.com/

Bora Pharmaceuticals Co., Ltd. is a global pharmaceutical service provider that operates through a "dual-engine" business model, integrating comprehensive Contract Development and Manufacturing Organization (CDMO) services with the development and commercialization of specialty pharmaceuticals. The company provides end-to-end solutions ranging from formulation development and clinical trial materials to large-scale commercial manufacturing. Its technical capabilities encompass a diverse array of dosage forms, including oral solids, liquids, and semi-solids. With a manufacturing footprint spanning multiple continents, the company serves global markets by leveraging advanced production technologies and rigorous quality management systems. Bora Pharmaceuticals focuses on strategic growth through acquisitions and partnerships, aiming to enhance manufacturing efficiency and accelerate the delivery of complex therapeutic treatments to patients worldwide.

Recent filings

Filing Released Lang Actions
公告本公司對子公司背書保證餘額達「公開發行公司資金貸與 及背書保證處理準則」第二十五條第一項第三款
Regulatory Filings Classification · 80% confidence The text is a regulatory disclosure from Taiwan’s Market Observation Post System (公開資訊觀測站) by listed company 6472 regarding guarantee/endorsement limits to a subsidiary under the “公開發行公司資金貸與及背書保證處理準則.” It is a mandatory compliance announcement, not a standalone financial report or itemized category like dividends, share issues, or M&A. This fits the fallback “Regulatory Filings” category.
2026-05-13 Chinese
公告本公司對子公司背書保證餘額達「公開發行公司資金貸與 及背書保證處理準則」第二十五條第一項第四款
Regulatory Filings Classification · 85% confidence The document is a mandatory regulatory disclosure on the Taiwan “公開資訊觀測站” system announcing that the company’s endorsement/guarantee balance to its subsidiary has reached a threshold under the “公開發行公司資金貸與及背書保證處理準則.” It is not an actual financial report, earnings release, or capital-raising announcement but a compliance filing under exchange rules, so it falls into the general Regulatory Filings category (RNS).
2026-05-13 Chinese
115年05月法人說明會簡報 — 647220260513E003.pdf
Investor Presentation Classification · 90% confidence The document is a slide‐based presentation titled “1Q26 Earnings Release” with forward‐looking statements, quarterly financial tables, business segment highlights, strategic outlook and ESG achievements. It goes beyond a simple press release of results and is structured as an investor slide deck. Therefore it is best classified as an Investor Presentation.
2026-05-13 English
115年05月法人說明會簡報 — 647220260513M003.pdf
Investor Presentation Classification · 92% confidence The document is a slide presentation titled “1Q26 Earnings Release” containing forward-looking statement disclaimers, charts and tables of quarterly financial results, strategic milestones, market outlook, and ESG metrics. It is formatted as an investor deck rather than a formal regulatory filing or press release, matching the definition of an Investor Presentation.
2026-05-13 English
115年05月法人說明會簡報 — 647220260513E001.pdf
Investor Presentation Classification · 95% confidence The document is a slide-based overview of the company’s 1Q26 financial results and strategic updates, complete with forward-looking disclaimers, detailed segment metrics, charts, and investor-focused narrative. It is not a transcript, press release, or regulatory filing but a comprehensive investor presentation deck, matching the definition of IP (Investor Presentation).
2026-05-13 English
115年05月法人說明會簡報 — 647220260513M001.pdf
Investor Presentation Classification · 94% confidence The document is a slide-based presentation deck that includes forward-looking disclaimers, detailed financial tables (1Q26 results), strategic milestones, CDMO business updates, ESG metrics, and global network maps. It is structured as an investor presentation rather than a brief earnings press release or the formal annual or interim report. Therefore, it fits the Investor Presentation category.
2026-05-13 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.